See every side of every news story

Published 12 days ago • loading... • Updated 12 days ago

Johnson & Johnson Reports Three-Year Crohn's Drug Results

Summary by MyChesCo

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 clinical trial results showing sustained remission in patients receiving its Crohn’s disease treatment Tremfya for three years, …

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

Johnson & Johnson Reports Three-Year Crohn's Drug Results

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 clinical trial results showing sustained remission in patients receiving its Crohn’s disease treatment Tremfya for three years, …

12 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated12 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MyChesCo broke the news 12 days ago on Friday, October 23, 2026.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics